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The androgen receptor (AR) initiates important developmental
and oncogenic transcriptional pathways. The AR is known to bind
as a homodimer to 15-base pair bipartite palindromic androgen-
response elements; however, few direct AR gene targets are
known. To identify AR promoter targets, we used chromatin
immunoprecipitation with on-chip detection of genomic frag-
ments. We identified 1,532 potential AR-binding sites, including
previously known AR gene targets. Many of the new AR target
genes show altered expression in prostate cancer. Analysis of
sequences underlying AR-binding sites showed that more than
50% of AR-binding sites did not contain the established 15bp
AR-binding element. Unbiased sequence analysis showed 6-bp
motifs, which were significantly enriched and were bound directly
by the AR in vitro. Binding sequences for the avian erythroblastosis
virus E26 homologue (ETS) transcription factor family were also
highly enriched, and we uncovered an interaction between the AR
and ETS1 at a subset of AR promoter targets.
Keywords: androgen receptor; chromatin immunoprecipitation;
ETS1; microarray; prostate cancer
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INTRODUCTION
The transcriptional function of the androgen receptor (AR) is
essential for normal male sexual development and drives the
onset, and subsequent progression, of prostate cancer (PrCa; Chen
et al, 2004; Notini et al, 2005). PrCa is the most common solid
malignancy in men in the EU, and resulted in more than 85,000
deaths in 2004 alone (Boyle & Ferlay, 2005). Many of the current
biomarkers of PrCa are androgen-regulated genes, including
prostate-specific antigen (human glandular kellikrein (KLK3)/
PSA), illustrating the enhanced AR activity in PrCa. Androgen
ablation is an effective first-line therapy for the treatment of
advanced PrCa; however, recurrence is common and is associated
with androgen independence (Scher et al, 1997). Despite loss of
response to anti-androgens, most advanced PrCa express AR and
have an active AR signalling cascade (van der Kwast et al, 1991).
Cell line models also suggest that the AR is required for androgen-
independent PrCa cell growth (Haag et al, 2005). It is important to
identify the main pathways downstream of AR transactivation that
might mediate the ‘androgen-independent’ function of the AR.
These pathways are likely to contribute to the growth and
progression of PrCa, and might include new candidate biomarkers
or future therapeutic targets.
The activated AR is known to bind as a homodimer to
androgen-response elements (AREs), which consists of two 6-base
pair ‘half-sites’ arranged as inverted or direct repeats separated by
3bp. The in vitro-derived (SELEX) consensus sequence for the AR
was found to be the inverted repeat 50-AGAACAnnnTGTACC-30
(Roche et al, 1992). However, sequence alignment of known AR
genomic binding sequences reveals both inverted repeat and
direct repeat consensus sequences (Verrijdt et al, 2003). This
degeneracy of functional AREs, and also the divergence from the
in vitro-derived binding sequence, make computational prediction
of AR-binding sites in the human genome problematic. Alternative
approaches have therefore been taken to identify AR-regulated
genes. Several studies have used expression microarray techniques
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871to identify AR transcriptional targets (Waghray et al, 2001; Chen
et al, 2004; Velasco et al, 2004; Haag et al, 2005). Although these
approaches have successfully identified androgen-regulated tran-
scriptional events, they cannot discern direct gene targets of the
AR from secondary transcriptional events. Therefore, such
expression studies neither give insights into the genomic
sequences that are bound by the AR nor identify the initiating
signals that ultimately produce the large number of downstream
androgen-regulated transcriptional events. To identify direct
transcriptional targets of the AR, we used chromatin immuno-
precipitation (ChIP) with on-array detection (ChIP-chip) in the
androgen-responsive LNCaP PrCa cell line.
RESULTS AND DISCUSSION
AR ChIP-chip analysis
LNCaP cells were androgen deprived before stimulation with a
synthetic androgen (R1881) or vehicle (ethanol). Using ChIP, an
AR antibody was labelled and hybridized to an array with a tiling
coverage of 24,275 gene promoter regions. Data from biological
replicate AR ChIP-chip experiments were filtered by signal
intensity (4twofold increase in androgen versus vehicle), repro-
ducibility (Wilcoxon P-value p0.01) and probe coverage (4four
probes contributing to these scores; see the supplementary
information online for details). This analysis identified as potential
AR-binding sites 1,532 promoter regions that were more than
twofold enriched in androgen-stimulated cells compared with
vehicle-treated cells (Fig 1A; see supplementary Table 1 and
supplementary information online).
The thresholds for AR ChIP-chip allowed detection of 15
known direct AR target genes identified using literature searches
(supplementary Table 2 online). These 15 known AR targets show
a range of AR ChIP-chip enrichment values. For example, the
well-studied AR targets in the carbonic anhydrase 3, PSA and
pepsinogen C promoters had enrichment scores of 2.26, 2.51 and
4.46, respectively, suggesting that direct AR targets were present
even among the lower scoring candidates. There are, at present,
several examples in the literature of direct AR gene targets;
therefore, to identify a larger number of androgen-responsive
genes in our AR ChIP-chip data, we compared our data with gene
lists from a published meta-analysis of six gene expression data
sets, all of which used the LNCaP cell line to identify androgen-
regulated genes (Velasco et al, 2004; see the supplementary
information online for details). We identified 92 genes that were
enriched by AR ChIP-chip and were also androgen regulated in
one or more expression data sets (supplementary Table 3 online),
making them strong candidates for direct transcriptional regula-
tion by the AR in response to androgen stimulation (see the
supplementary information online).
To validate our AR ChIP-chip promoter targets, a set of 26 gene
promoters with a range of enrichment and significance scores
were assessed by independent AR-ChIP and quantitative PCR
(Fig 1A,B). Three known AR-binding sites in the diazepam-binding
inhibitor, KLK2 and KLK3 promoters (Young et al, 1992; Murtha
et al, 1993), and 23 new, randomly selected gene promoters were
assessed. There was an increase in AR binding at 23 promoters,
after 1h of androgen exposure, suggesting a false discovery rate of
approximately 13% in the AR ChIP-chip data (Fig 1B). AR
recruitment was also assessed in the DUCaP PrCa cell line at eight
candidate promoters. Six of these promoters were enriched in
androgen-treated DUCaP cells (Fig 1C), suggesting that many of
the AR-binding sites identified by ChIP-chip in LNCaP cells might
be common AR targets in PrCa cells.
AR target genes
Gene Ontology analysis of the 1,532 genes associated with AR
ChIP-chip-enriched promoters showed AR target genes to be
involved in protein synthesis, development, secretion, apoptosis
and transcription (Fig 2A; supplementary Table 4 online). To
assess the clinical relevance of these AR ChIP-chip target genes,
we retrieved expression values for these genes from publicly
available clinical PrCa expression array data sets (Holzbeierlein
et al, 2004; Varambally et al, 2005; Tomlins et al, 2007).
Interestingly, we found genes that were overexpressed in primary
PrCa and metastatic PrCa compared with benign prostate
epithelia, and also genes that were downregulated after androgen
ablation therapy (Fig 2A; supplementary Table 4 online). Further
comparisons with published expression array gene lists from cell
line experiments showed subsets of AR target genes upregulated in
response to androgen treatment and genes that were down-
regulated after RNA interference (RNAi) ‘knock-down’ of the AR
in LNCaP cells (Fig 2A; supplementary Table 4 online; Velasco
et al, 2004; Haag et al, 2005).
The 92 AR target genes, which were also found to be androgen
regulated in LNCaP cells, represent the strongest candidates for
direct AR transcriptional targets (Fig 2A; supplementary Table 3
online). Several of these androgen-regulated AR gene targets were
overexpressed in primary PrCa samples compared with benign
samples in two independent clinical expression array data sets
(Fig 2B,E; Varambally et al, 2005; Tomlins et al, 2007). AR target
genes with Gene Ontology annotations for development and
transcription had increased expression in primary PrCa and a
subset was also upregulated in metastatic PrCa (Fig 2C,D). The
upregulation of AR targets with transcriptional annotations
suggests complex transcriptional changes downstream of the AR
that might be activated in PrCa. These analyses show that many of
the direct AR target genes identified by ChIP-chip analysis have
cancer-related functional annotations, are upregulated in clinical
PrCa and might therefore have potential as biomarkers or future
therapeutic targets.
Binding site analysis
We examined the 1,532 AR-binding sites identified by ChIP-chip
for the presence of ARE-like sequences, to determine the preferred
binding sequences of the AR. Although the occurrence of 15-bp
ARE sequences was enriched in the AR promoter targets compared
with non-candidate promoters (w2 test, Po2 10 6), only 410
(26.8%) of the 1,532 AR promoter-binding sites contained
sequences that resembled the established 15-bp AREs (Fig 3A,B).
The AR ChIP targets, which were identified as androgen-regulated
genes in published expression array data, had an equal occurrence
of AREs (26 of 92 genes, 28%), suggesting that functional AR target
genes might lack the established 15-bp AR-binding sequence.
To identify conserved sequences in the AR-bound promoters in
an unbiased manner, we used the Nested Motif Independent
Component Analysis (MICA) motif recognition software (Down
& Hubbard, 2005). Nested MICA analysis using a ‘training set’ of
225 AR ChIP-chip-enriched sequences did not identify any over-
represented sequences that resembled the established 15-bp ARE
AR binds to 6-bp ‘half-sites’ and associates with ETS1
C.E. Massie et al
EMBO reports VOL 8 | NO 9 | 2007 &2007EUROPEAN MOLECULAR BIOLOGY ORGANIZATION
scientificreport
872sequence. However, several frequently occurring and highly
constrained motifs were present among the Nested MICA searches
for enriched 6-bp motifs (supplementary Fig S1A,B online).
Among the most frequently occurring non-repetitive motifs were
two that resembled one-half of the 15-bp ARE sequences (motifs 2
and 6; Fig 3A,C). The more constrained motif 2 AR ‘half-site’, which
aligned to one-half of the 15-bp ARE sequence (Fig 3A,C), was
used for subsequent sequence analysis. This 6-bp AR ‘half-site’
occurred in 1,212 (79.2%) of the AR candidate promoter
sequences, including 876 (57.2%) of the AR ChIP-chip sequences
that did not contain a 15-bp ARE sequence (Fig 3D), and was
enriched in the AR ChIP-chip candidate promoters compared with
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Fig 1 |Androgen receptor-bound gene promoters identified by ChIP-chip. (A) AR ChIP-chip profiles of eight AR target gene promoters from vehicle
(þEtOH)- and androgen (þR1881)-treated experiments. Genomic locations are indicated on the x axis and enrichment compared with total input
DNA is shown on the y axis. (B) AR ChIP and qPCR analysis of 26 AR promoter targets in LNCaP cells. (C) AR ChIP and qPCR analysis of eight
promoter targets in DUCaP cells. Relative enrichment by ChIP was quantified by using the standard curve method following 1h with vehicle (EtOH)
or androgen (R1881) relative to b-actin control and total genomic DNA input (see the supplementary information online for details). Values are the
averages of replicate experiments. Enrichment scores (S) and Wilcoxon scores (W) from LNCaP AR ChIP-chip analysis are indicated next to
corresponding genes. AR, androgen receptor; ChIP, chromatin immunoprecipitation; ChIP-chip, ChIP with on-array detection; Chr, chromosome;
EtOH, ethyl alcohol; KLK, human glandular kellikrein; qPCR, quantitative PCR.
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Po2 10 5).
We used an in vitro oligonucleotide pull-down assay to
examine AR binding to the 6-bp AR ‘half-site’. As a positive
control, the AR was shown to bind to the KLK2 promoter ARE
sequence more strongly than a scrambled 15-bp oligonucleotide
(Fig 3E,F). The AR also bound specifically to the 6-bp AR ‘half-site’
sequence from the UNQ9419 promoter, but not a scrambled
control oligonucleotide (Fig 3E,F), showing that the AR can bind
directly to these 6-bp ‘half-sites’. To examine AR recruitment to
in vivo 6-bp ‘half-sites’, we used AR ChIP and quantitative PCR
for the UNQ9419 promoter region, which lacks a 15-bp ARE
sequence (Fig 3G,H). ChIP analysis showed androgen-dependent
recruitment of the AR to the UNQ9419 promoter at a level similar
to that of the KLK2 promoter (Fig 3I,K). An androgen treatment
time course showed transient UNQ9419 upregulation and
sustained upregulation of KLK2 expression (Fig 3J,L). These data
show that the AR can bind directly to 6-bp ‘half-sites’ and that AR
transactivation might occur in genes adjacent to these 6-bp
AR-binding sites. Direct AR binding to 6-bp ‘half-sites’ raises
important questions about our understanding of AR biology and
further work will be required to determine the mechanism by
which AR is recruited to these ‘half-sites’ (see supplementary
Fig S1C online for potential models).
AR interacts with the ETS1 transcription factor
Further sequence analysis using the Genomatix Matbase program
(Cartharius et al, 2005) and Nested MICA identified frequent
consensus binding sequences for the avian erythroblastosis virus
E26 homologue (ETS) family of transcription factors (Fig 4A; see
the supplementary information online). The ETS-like Nested MICA
motif 9 and AR 6-bp ‘half-site’ co-occurred in 1,073 (70%) of the
AR-enriched promoters (w2 test, Po2 10 8), suggesting that
there might be co-recruitment of ETS transcription factors and the
AR to a subset of promoters. To investigate further the association
of AR and ETS, we selected the ETS1 transcription factor as a
candidate, as the ETS1-binding site was among the most common
ETS sequence motifs found in the AR ChIP-chip promoters (as
identified by Genomatix Matbase) and ETS1 was recently reported
to be overexpressed in PrCa (Alipov et al, 2005).
Using ChIP, an ETS1 antibody showed that ETS1 was
associated with a subset of AR-bound promoters (Fig 4B,C). The
CCNG2 and UNQ9419 promoters contain predicted ETS1-
binding sites (Fig 4B) and showed androgen-dependent recruit-
ment of both the AR and ETS1 by ChIP (Figs 1B,4C). However, the
PRAME promoter does not contain a predicted ETS1-binding site
(Fig 4B) and was not enriched by ETS1 ChIP (Fig 4C). Knockdown
of endogenous ETS1 by RNAi resulted in a matched reduction in
CCNG2 and UNQ9419 transcripts, but did not affect the level of
PRAME transcript (Fig 4D). Conversely, ETS1 overexpression
resulted in enhanced transcription of CCNG2 and UNQ9419,
but not PRAME (Fig 4E). Confocal microscopy showed that
endogenous ETS1 was located throughout LNCaP cells grown in
steroid-depleted media and was redistributed to the nucleus
together with transfected AR–green fluorescent protein (GFP;
Fig 4F) or endogenous AR (Fig 4G) in LNCaP cells on androgen
treatment. In an AR luciferase reporter assay, ETS1 transfection
enhanced AR transactivation in an AR- and androgen-dependent
manner (supplementary Fig S2F online). The AR was co-
immunoprecipitated using an ETS1 antibody, suggesting a direct
interaction between the AR and ETS1 in LNCaP cells (supple-
mentary Fig S2D online). These data indicate androgen-dependent
recruitment of ETS1 to a subset of AR promoter targets and also
that endogenous ETS1 is required for expression of these AR target
genes (see the supplementary information online).
Speculation
Recruitment of the AR to 6-bp ‘half-sites’ raises the question of
how the AR is selectively recruited to its targets in large
mammalian genomes. This might occur by co-operative binding
with other factors, such as ETS1. As ETS1 is recruited to AR
promoter targets in response to androgens, it is unlikely that ETS1
acts as a ‘pioneer factor’ for the AR, as has been reported for
FOXA1 and the estrogen receptor (Carroll et al, 2005; Laganiere
et al, 2005). The implication that ETS transcription factors
transactivate the AR might have an impact on our understanding
of the functional effects of TMPRSS2-ETS gene fusions given the
prevalence of this rearrangement in PrCa (Tomlins et al, 2005).
METHODS
Cell culture and transfection. LNCaP and DUCaP cells were
grown in RPMI (Invitrogen, Paisley, UK) media supplemented with
10% FBS. Cells were transfected with the GeneJuice transfection
reagent (Merck, Nottingham, UK), according to the manufacturer’s
instructions. The pSG5–ETS1 expression construct was a kind gift
from Dr A. Be `gue (Baillat et al, 2002).
Chromatin immunoprecipitation. Cells were grown to 70–80%
confluence in phenol-red-free RPMI (Invitrogen) supplemented
with 10% charcoal-stripped FBS (HyClone, Logan, UT, USA) for
48h before stimulation with 1 10 9M R1881 (synthetic andro-
gen) or an equal volume of ethanol for 1h. ChIP was carried out as
previously described, using 5mg of AR (N20, Santa Cruz) or ETS1
(C20, Santa Cruz, Biotechnology, Santa Cruz, CA, USA) anti-
bodies (see the supplementary information online for details;
Oberley et al, 2003).
ChIP-chip. Biological replicate hybridizations were carried out
for AR ChIP from LNCaP cells stimulated for 1h with R1881 or
ethanol (vehicle), co-hybridizing with labelled total genomic DNA
Fig 2 |Functional annotation of androgen receptor ChIP target genes. (A) AR ChIP-chip target gene-enriched Gene Ontology categories and gene
expression changes identified by comparing results with publicly available expression array data. (B–E) Heat-maps showing changes in gene expression
for individual clinical samples, taken from publicly available expression array data (Varambally et al, 2005), for sets of genes identified as androgen-
regulated (B), involved in transcription (C) and development (D). (E) Gene expression heat-map from a separate clinical expression array study for
AR target genes that were identified as androgen-regulated (Tomlins et al, 2007). Arrows in B and E indicate that the expression of the genes selected
have been reported to be upregulated on androgen treatment in previous studies. AR, androgen receptor; BN, benign; ChIP, chromatin
immunoprecipitation; ChIP-chip, ChIP with on-array detection; EPI-BPH, benign prostatic hyperplasia; EPI-NORM, normal prostate epithelium;
GO, Gene Ontology; KLK, human glandular kellikrein; MET, metastatic PrCa; PrCa, primary PrCa.
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(F) AR western blot of oligonucleotide pull-down fractions, as indicated. Low-molecular-weight region of a parallel Coomassie blue-stained gel shows
equal loading of cell lysates. (G,H) UCSC Genome Browser tracks showing 15-bp ARE and 6-bp AR ‘half-site’ occurrence in KLK2 and UNQ9419 pro-
moters. (I,K) AR ChIP and qPCR for KLK2 (I) and UNQ9419 (K)p r o m o t e r sf r o mv e h i c l e(þEtok)-and androgen (R1881)-treated experiments. (J,L)C e l l s
were maintained in ethanol (þE) or treated on a time course with androgen (þR; R1881) for 18h. Material was harvested at 1, 4 and 18h during the
time course and subjected to qrtPCR for KLK (J) and UNQ9419(L), respectively. AR, androgen receptor; ARE, androgen-response element; ChIP, chromatin
immunoprecipitation; ChIP-chip, ChIP with on-array detection; Chr, chromosome; KLK2, human glandular kellikrein; qrtPCR, quantitative real-time PCR.
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Fig 4 |ETS1 and androgen receptor interaction. (A) Sequence logos for ETS1 and AR ChIP-chip-enriched motifs 9 and 1. (B)U C S CG e n o m eB r o w s e rt r a c k s
showing 15-bp ARE, 6-bp AR ‘half-site’ and ETS1 motif occurrence in UNQ9419, CCNG2 and PRAME promoters. Locations of AR ChIP-chip peaks are
indicated; darker boxes represent higher signal. (C) ETS1 ChIP and qPCR for UNQ9419, CCNG2 and PRAME promoters from vehicle (þEtOH)- and
androgen (R1881)-treated experiments. (D,E) Quantitative real-time PCR of ETS1, UNQ9419, CCNG2 and PRAME 48h after transfection with an ETS1
RNAi construct (pSR-ETS1) or a scrambled control (pS-Scr) (D) and ETS1 expression construct (þETS1) or an empty vector control (pSG5) (E). qPCR
data were quantified using the standard curve method, values relative to control sample and averages of replicate experiments. (F,G) Confocal microscopy
images of LNCaP cells treated with androgen (þR1881) or vehicle (þEtOH) for 1h. Cells were transfected with either AR–GFP expression construct (F)
or pSG5 empty vector (G) and stained for AR (N20) and ETS1 (C20 and 1G11), as indicated. AR, androgen receptor; ARE, androgen-receptor elements;
ChIP, chromatin immunoprecipitation; ChIP-chip, ChIP with on-assay detection; DAPI, 40,6 0-diamidino-2-phenylindole; ETS, avian erythroblastosis virus
E26 homologue; GFP, green fluorescent protein; qPCR, quantitative PCR; RNAi, RNA interference.
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877to NimbleGen Systems (Madison, WI, USA) 1.5kb promoter
arrays. Raw data for AR ChIP-chip experiments is available
through ArrayExpress (accession E-TABM-233, http://www.ebi.
ac.uk/arrayexpress/). Array analysis was carried out using the
limma package in the R statistical software (see the supplementary
information online for details).
Sequence analysis. Nested MICA motif recognition software
(v0.7.2) was used to identify conserved sequence motifs in a
‘training’ set of 225 highly enriched AR target sequences (see
supplementary Table 5 and supplementary information online for
details). Searches for the AR, ETS1 and the conserved 6bp Nested
MICA sequence motifs were carried out on all 1,532 AR ChIP-chip
targets, using the position weight matrices shown in supplementary
Table 6 online (see the supplementary information online for details).
Quantitative real-time PCR. Real-time quantitative PCRs were
carried out in an ABI Prism 7900, using SYBRgreen PCR master
mix (Applied Biosystems, Warrington, UK). Reactions were
carried out in triplicate and with biological replicates. Primers
are shown in supplementary Table 7 online.
Immunoprecipitation. LNCaP cells lysates were incubated with
AR (N20, Santa Cruz), ETS1 (C20, Santa Cruz) or control rabbit
IgG antibodies. Immune complexes were isolated on protein-A/G
beads, washed four times with RIPA buffer and resuspended in sample
loading buffer, before western blotting for AR (N20, Santa Cruz).
Oligo pull-down. Oligonucleotide pull-down assays using LNCaP
cell lysates were carried out as described previously (see the
supplementary information online for details; Hata et al, 2000).
Immunofluorescence. LNCaP cells on coverslips were treated,
transfected and stained for AR (AR-N20, Santa Cruz) and ETS1
(C20, Santa Cruz or 1G11, Novocastra Laboratories, Newcastle
upon Tyne, UK) as indicated (see the supplementary information
online for details).
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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